Carna BiosciencesCarna Biosciences, Inc.4572東証グロース医薬品FY ending Dec 2025, consolidated, J-GAAP

Carna Biosciences FY ending Dec 2020 results

About 95% of Carna Biosciences's sales come from Drug discovery support business, with Drug discovery business making up much of the rest.

It lost about ¥93 for every ¥100 of sales at the operating level.

Revenue changed -64.7% from the prior year, operating profit -208.1%.

Revenue and profit pattern

Turned to a loss

FY ending Dec 2019 → FY ending Dec 2020

FY ending Dec 2019 → FY ending Dec 2020

For every ¥100 Carna Biosciences sells, how much goes where, and how much is kept.

FY ending Dec 2020

Gross margin83.0%

Operating margin-93.3%

Net margin-98.0%

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Revenue by business segment, and the profit each one keeps.

FY ending Dec 2020

Drug discovery support business¥1.08B
95%
Op. margin 42.5%Industry: CRO & Clinical Testing
Drug discovery business¥53M
5%
Op. margin -2858.7%Industry: Biotech & Regenerative Medicine

※ Segment figures include inter-segment sales and do not sum to the company total

Show source documents (5)

EDINET (FSA Japan)
有価証券報告書－第22期(2024/01/01－2024/12/31)
ID S100VEU52025-03-26Open
EDINET (FSA Japan)
有価証券報告書－第21期(2023/01/01－2023/12/31)
ID S100T2Q72024-03-27Open
EDINET (FSA Japan)
有価証券報告書－第20期(2022/01/01－2022/12/31)
ID S100QFB82023-03-27Open
EDINET (FSA Japan)
有価証券報告書－第19期(令和3年1月1日－令和3年12月31日)
ID S100NPCS2022-03-25Open
EDINET (FSA Japan)
有価証券報告書－第18期(令和2年1月1日－令和2年12月31日)
ID S100KZV22021-03-26Open

Extracted from XBRL: 44 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.